ReviewCancers2019
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The multiple roles of autophagy in uveal melanoma and the microenvironment.Journal of cancer research and clinical oncology · 2024Pooled it
- Additive Role of Immune System Infiltration and Angiogenesis in Uveal Melanoma Progression.International journal of molecular sciences · 2021Pooled it
- The Diagnostic and Prognostic Role of CombinedInternational journal of molecular sciences · 2026Review
- Disulfiram/Copper Combined with Irradiation Induces Immunogenic Cell Death in Melanoma.International journal of molecular sciences · 2026Article
- Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.BioImpacts : BI · 2026Review
- Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study.Journal of inflammation (London, England) · 2025Article
- Identification of feature genes and molecular mechanisms involved in cell communication in uveal melanoma through analysis of single‑cell sequencing data.Oncology letters · 2024Article
- Malignant melanoma complicated with cataract and secondary glaucoma: A case report.Oncology letters · 2024Article
- Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.Biomarker research · 2024Article
- From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.Current oncology (Toronto, Ont.) · 2024Review
- Beneath the surface: a case report of metastatic iridociliary ring melanoma treated with pembrolizumab.Arquivos brasileiros de oftalmologia · 2024Article
- Detection of neoplastic-immune hybrid cells with metastatic properties in uveal melanoma.Research square · 2023Article
- Cross talk between tumor stemness and microenvironment for prognosis and immunotherapy of uveal melanoma.Journal of cancer research and clinical oncology · 2023Article
- Identification of co-expressed gene networks promoting CD8BMC ophthalmology · 2023Article
- FGF-trapping hampers cancer stem-like cells in uveal melanoma.Cancer cell international · 2023Article
- Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis.Cell discovery · 2023Article
- Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients.Cancers · 2023Article
- Digital Quantification of Intratumoral CD8+ T-Cells Predicts Relapse and Unfavorable Outcome in Uveal Melanoma.Cancers · 2022Article
- Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma.Dermatologic therapy · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.